- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03616808
Thromboelastometry-identified Haemostatic Changes in Isolated Traumatic Brain Injury (THROMBIN)
The Influence of Thromboelastometry-identified Haemostatic Changes on Haemorrhagic Progression of Intracranial Injury and Clinical Outcome in Patients With Isolated Traumatic Brain Injury
Study Overview
Status
Intervention / Treatment
Detailed Description
Aim of the study:
To assess the utility of thromboelastometry for identification of hemostatic changes, goal-directed coagulation management, and prognosis of intracranial hemorrhagic injury progression as well as clinical outcome in patients with isolated traumatic brain injury.
Objectives:
To evaluate perioperative prevalence and characteristics of thromboelastometry identified coagulopathy in neurosurgical patients with isolated traumatic brain injury; To assess the correlation between routine laboratory test results and thromboelastometric findings; To evaluate the influence of thromboelastometric findings and goal-directed coagulation management on the progression of intracranial hemorrhagic injury; To evaluate the utility of thromboelastometry for goal-directed coagulation management, and its possible influence on clinical outcome.
Study background:
Traumatic brain injury still accounts for a considerable proportion of preventable deaths worldwide. The prevalence of coagulation derangements among patients with traumatic brain injury (TBI) is high and approximates 30 % (1,2). The main hypothesis explaining the development of coagulopathy in the absence of massive bleeding is extensive release of tissue factor from the damaged brain tissue and subsequent over-activation of coagulation leading to consumption of coagulation substrates. The presence of coagulopathy in the setting of TBI is associated with high risk of intracranial hemorrhagic insult progression and death (3,4). Many authors investigating coagulopathy associated with traumatic brain injury have used routine coagulation tests, such as APTT, PT, INR, fibrinogen levels. However, those tests do not reflect the overall clot quality and reflect only separate parts of the coagulation process.
Craniotomy for traumatic brain injury is an urgent high-risk procedure presenting a serious challenge for the anesthesiology team. Significant, diffuse bleeding is not infrequent, and the spectrum of neurosurgical hemostatic options is limited. Moreover, even small amounts of intracranial blood may be life-threatening. Therefore the maintenance of optimal physiologic clotting capacity is crucial. Literature data investigating the use of ROTEM in TBI patients is still limited (5,6).
The investigators believe that thromboelastometry could provide novel insights into the dynamic coagulation changes of TBI patients. Moreover, it could serve as a clinical tool for targeted coagulation management in the perioperative period of patients undergoing craniotomies for intracranial traumatic hematomas, and prove beneficial for patient outcome.
Materials and methods:
A prospective open-label case-control study will be performed. Adult isolated traumatic brain injury patients undergoing craniotomy and will be enrolled. Required sample size was calculated based on the average number of craniotomies performed to treat traumatic brain injury during the past five years in a tertiary neurosurgical centre. The investigators plan to enroll 70 patients into the ROTEM-guided group (Cases), and 70 patients into the conventional therapy group (Controls). All patients will undergo standard coagulation analysis (APTT, PT, INR, fibrinogen levels, platelet count) preoperatively, and 3 days postoperatively, whereas ROTEM-guided group patients will additionally be tested with ROTEM (EXTEM, INTEM, FIBTEM, APTEM). Coagulation management decisions in the ROTEM-guided group will be made according to a ROTEM-based algorithm for goal-directed hemostatic therapy. Conventional therapy group will be treated as usual. Perioperative demographic, clinical and laboratory data of study patients will be registered. Early neurological state (on postoperative days 1,2,3,7, and until discharge) will be assessed according to the Glasgow coma scale. Late neurological outcome (6 and 12 months postoperatively) will be assessed according to Glasgow outcome scale. Comparative analysis of Case and Control groups will be performed. Perioperative prevalence and characteristics of coagulopathy in neurosurgical patients with isolated traumatic brain injury will be estimated. Correlation between routine laboratory test results and thromboelastometric findings will be assessed. The influence of thromboelastometric findings and goal-directed coagulation management on the progression of intracranial hemorrhagic injury will be assessed. The influence of goal-directed coagulation management on clinical outcome will be evaluated.
Anticipated scientific and clinical benefits:
The investigators believe that ROTEM results could provide better insight into perioperative coagulation changes, be beneficial to patient blood management, and result in better outcome.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kaunas, Lithuania, LT-50009
- Hospital of Lithuanian University of Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Isolated traumatic brain injury (within 48 hours) (AIS head >= 3)
- Urgent craniotomy is necessary
- A written informed consent is acquired from the patient or his/her representative
Exclusion Criteria:
- Refusal / inability to acquire an informed consent
- Significant trauma to other body regions (AIS other regions >= 3)
- Data on significant chronic hepatic or hematologic illness
- Use of oral anticoagulants or antiplatelet agents
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Conventional therapy
Intraoperative haemostatic treatment is based on conventional coagulation assays.
|
|
Active Comparator: Goal-directed therapy
Thromboelastometry-guided haemostatic treatment is provided intraoperatively.
|
Administration of blood products and/or procoagulants is based on thromboelastometric assays.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: 30 days
|
Mortality of patients in both groups
|
30 days
|
Early neurological state according to Glasgow coma scale
Time Frame: 30 days
|
Glasgow coma scale (GCS) is used to objectively assess the level of consciousness after neurological injury according to best eye (range 1 to 4), verbal (range 1 to 5) and motor (range 1 to 6) response of the patient.
Eye, verbal and motor scores are summed to give the total Glasgow coma score (range 3 to 15).
The lowest possible GCS (the sum) is 3 (deep coma or death), while the highest is 15 (fully awake person).
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Coagulation abnormalities on conventional coagulation assays and ROTEM
Time Frame: 72 hours
|
The number of patients with abnormal results of PT (prothrombin time), INR (international normalized ratio), APTT (activated partial thromboplastin time), fibrinogen concentration, platelet count and/or any abnormal thromboelastometric (ROTEM) parameter
|
72 hours
|
Progressive hemorrhagic injury
Time Frame: 30 days
|
Evidence of new or increased intracranial hemorrhagic injury
|
30 days
|
Clinical outcome according to Glasgow outcome score
Time Frame: Up to 1 year
|
The Glasgow Outcome Score (GOS) is used to divide patients with traumatic brain injury into groups (range 1 to 5) that allow standardised descriptions of the objective degree of recovery as follows:
|
Up to 1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between conventional coagulation assays and ROTEM parameters
Time Frame: 72 hours
|
The number of cases with corresponding results (both abnormal (or normal) conventional coagulation assays and ROTEM parameters) vs. the number of cases with conflicting results (abnormal (or normal) conventional coagulation assays, but normal (or abnormal) ROTEM parameters); Correlation between PT and EXTEM CT (thromboelastometric measure of clotting time in the extrinsic coagulation pathway); Correlation between APTT and INTEM CT (thromboelastometric measure of clotting time in the intrinsic coagulation pathway); Correlation between fibrinogen concentration and FIBTEM MCF (thromboelastometric measure of maximum clot firmness in the fibrinogen polymerisation assay); Correlation between platelet count and EXTEM MCF (thromboelastometric measure of maximum clot firmness in the extrinsic coagulation pathway); Correlation between platelet count and INTEM MCF (thromboelastometric measure of maximum clot firmness in the intrinsic coagulation pathway)
|
72 hours
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Wafaisade A, Lefering R, Tjardes T, Wutzler S, Simanski C, Paffrath T, Fischer P, Bouillon B, Maegele M; Trauma Registry of DGU. Acute coagulopathy in isolated blunt traumatic brain injury. Neurocrit Care. 2010 Apr;12(2):211-9. doi: 10.1007/s12028-009-9281-1.
- Harhangi BS, Kompanje EJ, Leebeek FW, Maas AI. Coagulation disorders after traumatic brain injury. Acta Neurochir (Wien). 2008 Feb;150(2):165-75; discussion 175. doi: 10.1007/s00701-007-1475-8. Epub 2008 Jan 2.
- Maegele M. Coagulopathy after traumatic brain injury: incidence, pathogenesis, and treatment options. Transfusion. 2013 Jan;53 Suppl 1:28S-37S. doi: 10.1111/trf.12033.
- de Oliveira Manoel AL, Neto AC, Veigas PV, Rizoli S. Traumatic brain injury associated coagulopathy. Neurocrit Care. 2015 Feb;22(1):34-44. doi: 10.1007/s12028-014-0026-4.
- Brazinova A, Majdan M, Leitgeb J, Trimmel H, Mauritz W; Austrian Working Group on Improvement of Early TBI Care. Factors that may improve outcomes of early traumatic brain injury care: prospective multicenter study in Austria. Scand J Trauma Resusc Emerg Med. 2015 Jul 16;23:53. doi: 10.1186/s13049-015-0133-z.
- Schochl H, Solomon C, Traintinger S, Nienaber U, Tacacs-Tolnai A, Windhofer C, Bahrami S, Voelckel W. Thromboelastometric (ROTEM) findings in patients suffering from isolated severe traumatic brain injury. J Neurotrauma. 2011 Oct;28(10):2033-41. doi: 10.1089/neu.2010.1744. Epub 2011 Sep 23.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Craniocerebral Trauma
- Trauma, Nervous System
- Hemostatic Disorders
- Blood Coagulation Disorders
- Brain Injuries
- Wounds and Injuries
- Brain Injuries, Traumatic
- Coagulants
- Hemostatics
Other Study ID Numbers
- v2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bleeding
-
Ethicon, Inc.Guangzhou Bioseal Biotechnology Co., Ltd.Completed
-
Waihong ChungUnknownMetoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy (MANPURSE)Upper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
Ottawa Hospital Research InstituteRecruitingGastroIntestinal Bleeding | Anticoagulant-induced BleedingCanada
-
Ethicon, Inc.CompletedHemorrhage | Soft Tissue Bleeding | Hepatic Parenchyma BleedingUnited Kingdom, Belgium
-
Hyloris DevelopmentsRecruitingBleeding From Teeth | Bleeding ProphylaxisSpain, United States, Belgium, Croatia, Hungary, Romania
-
Boston Children's HospitalBaylor College of Medicine; Children's Hospital of Philadelphia; Ann & Robert... and other collaboratorsRecruitingUpper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
Wake Forest University Health SciencesCompletedBleeding ComplicationUnited States
-
Chinese University of Hong KongCompletedGastrointestinal Bleeding | Bleeding Peptic Ulcer | Active BleedingChina
-
Chinese University of Hong KongBeijing Friendship Hospital; The First Affiliated Hospital of Soochow University and other collaboratorsCompletedAcute Upper Gastrointestinal Bleeding | Tumor BleedingHong Kong, China, Australia
-
Women and Infants Hospital of Rhode IslandActive, not recruitingAbnormal Uterine Bleeding | Abnormal Uterine Bleeding, Ovulatory Dysfunction | Abnormal Uterine Bleeding, Endometrial Hemostatic DysfunctionUnited States
Clinical Trials on Thromboelastometry-guided haemostatic treatment
-
Children's Hospital Los AngelesCompleted
-
University of Texas Southwestern Medical CenterCompletedTraumaUnited States
-
Hospital Israelita Albert EinsteinCompletedBleeding | Liver Transplant; Complications | Hemostatic Disorder
-
Tampere University HospitalWithdrawnBlood Loss, Surgical | Coagulation Defect; Acquired | Blood Loss Requiring TransfusionFinland
-
Young-Hak Kim, MD, PhDRecruitingCoronary DiseaseKorea, Republic of
-
University of LouisvilleNational Institute of General Medical Sciences (NIGMS)Not yet recruiting
-
GlaxoSmithKlineMacroStatCompleted
-
Massachusetts General HospitalRecruitingChronic PainUnited States
-
University of California, San DiegoHRSA/Maternal and Child Health BureauCompletedPediatric ObesityUnited States
-
NycomedCompletedTachoSil® Versus Standard Haemostatic Treatment of Haemorrhage in Cardiovascular Surgery (TC-023-IM)Haemorrhage | Cardiovascular Surgery | HaemostasisDenmark